FTC & PBMs: So What?
Executive SummaryThe FTC's August announcement of its settlement agreement with Merck/Medco Managed care outlined rules governing the PBM's relationaship with Merck & Co. Inc. The FTC's aggressive tone--which suggested that Medco acknowledged that past actions in promoting Merck drugs restricted competition and resulted in higher prices for some drugs--made the agreement seem like a victory for the FTC and upset Medco officials who concede no such things.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.